Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Erythrokeratoderma 'en cocardes' is a rare genodermatosis characterized by circumscribed target-like (or 'en cocardes') erythematous hyperkeratotic lesions. These lesions, which remit and recur, affect the trunk and extremities and are accompanied by scaly plaques evocative of erythrokeratoderma variabilis. Onset usually occurs at birth or during early childhood. Only few cases have been described. Transmission is autosomal dominant.
Features include very common findings: Thickened, rough skin (hyperkeratosis), Skin color changes (abnormality of skin pigmentation), Neoplasm of the skin, and Papule; and sometimes findings: Neoplasm.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 4 | Thickened, rough skin (hyperkeratosis), Skin color changes (abnormality of skin pigmentation), Neoplasm of the skin |
Phenotype severity distribution: 4 very common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for erythrokeratoderma en cocardes.
10 publications have been identified in PubMed for erythrokeratoderma en cocardes. Research spans Case Report / Case Series (70%) and Review / Meta-Analysis (30%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 7 | 70% |
Data assembled from 4 of 12 sources · Last updated Sep 17, 2026, 9:26 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Neoplasm |
1 |
Neoplasm |
3 |
30% |
Sollitto CF (2026). [PMID: 41890462](https://pubmed.ncbi.nlm.nih.gov/41890462/). *Cureus*. [Case Report / Case Series]
Okamura K (2026). [PMID: 41127964](https://pubmed.ncbi.nlm.nih.gov/41127964/). *J Dermatol*. [Review / Meta-Analysis]
Song Q (2025). [PMID: 40486197](https://pubmed.ncbi.nlm.nih.gov/40486197/). *Front Med (Lausanne)*. [Case Report / Case Series]
Kumar S (2025). [PMID: 40674458](https://pubmed.ncbi.nlm.nih.gov/40674458/). *Br J Dermatol*. [Review / Meta-Analysis]
Hanifa H (2025). [PMID: 40624600](https://pubmed.ncbi.nlm.nih.gov/40624600/). *J Med Case Rep*. [Case Report / Case Series]
Mathur M (2025). [PMID: 40667493](https://pubmed.ncbi.nlm.nih.gov/40667493/). *Clin Case Rep*. [Case Report / Case Series]
Gupta V (2025). [PMID: 40357971](https://pubmed.ncbi.nlm.nih.gov/40357971/). *Indian J Dermatol Venereol Leprol*. [Case Report / Case Series]
Zhou Y (2025). [PMID: 41143224](https://pubmed.ncbi.nlm.nih.gov/41143224/). *JAAD Case Rep*. [Case Report / Case Series]
Tomasini D (2025). [PMID: 40469237](https://pubmed.ncbi.nlm.nih.gov/40469237/). *JID Innov*. [Case Report / Case Series]
Mohapatra L (2024). [PMID: 39139099](https://pubmed.ncbi.nlm.nih.gov/39139099/). *Clin Exp Dermatol*. [Review / Meta-Analysis]